Document Detail


Cardiac dysfunction associated with trastuzumab.
MedLine Citation:
PMID:  16907652     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The HER2/neu gene is amplified in approximately 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity.
Authors:
Karen Lisa Smith; Chau Dang; Andrew D Seidman
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  5     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-15     Completed Date:  2006-08-23     Revised Date:  2013-05-08    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  619-29     Citation Subset:  IM    
Affiliation:
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibodies, Monoclonal, Humanized
Breast Neoplasms / drug therapy*,  genetics,  secondary
Chemotherapy, Adjuvant
Clinical Trials as Topic
Female
Genes, erbB-2 / drug effects*,  genetics
Heart Diseases / chemically induced*,  diagnosis
Humans
Stroke Volume / drug effects
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; P188ANX8CK/trastuzumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Update on ethambutol optic neuropathy.
Next Document:  Potential side effects of renin inhibitors--mechanisms based on comparison with other renin-angioten...